ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Meta-analysis adds evidence to association between omega-3 supplementation and lower heart rate

Friendly User's Guide for the Timing of Nutritional Supplements

The Health Benefits of Manuka Honey

Increase Your Magnesium Intake

Love Your Lungs With Tomatoes and Apples

Top Tips to Boost Your Immunity

Essential Oils Lower Blood Pressure

Vitamin D supplementation could ease IBS symptoms

11 Amazing Health Benefits of Using Baking Soda

Nicotinamide riboside shows promise for treatment of Alzheimer’s disease

 
Print Page
Email Article

Benefits of Treating Behavioral, Functional Problems Caused by Alzheimer’s Disease

  [ 77 votes ]   [ Discuss This Article ]
www.ProHealth.com • January 10, 2003


A class of drugs known as cholinesterase inhibitors has a significant impact on behavioral problems and the ability to perform everyday tasks in patients with Alzheimer’s disease, according to a study led by researchers at the San Francisco VA Medical Center (SFVAMC) and UCSF.

The study, an analysis of data from multiple small studies, appears in the January 8, 2003 issue of the Journal of the American Medical Association. Known as a meta-analysis, the study applied sophisticated statistical methods to data from 29 trials that involved the treatment of Alzheimer’s disease (AD) with cholinesterase inhibitors (ChIs).

People with AD can suffer cognitive, behavioral or functional difficulties. ChIs have been previously shown to effectively treat cognitive difficulties such as memory loss, disorientation and loss of language skills, said Kristine Yaffe, MD, Chief of Geriatric Psychiatry at the SFVAMC and UCSF assistant professor of psychiatry, neurology and epidemiology and biostatistics.

“Until now, the jury has been out on whether these drugs really worked for behavioral and functional symptoms,” said Yaffe, senior author of the JAMA article.

The current analysis revealed that patients treated with ChIs scored slightly higher on standard tests used to assess behavioral and functional status in patients with mild to moderate AD. These kinds of small, statistically significant increases in scores often translate into large impacts on behavior-related health problems, Yaffe said.

Approximately 4 million Americans have Alzheimer’s disease, a progressive disorder that leads to varying degrees of dementia and for which there is currently no cure. The deterioration of the brain characteristic of Alzheimer’s disease most often results in cognitive difficulties, such as memory loss.

About half the people suffering from the disease experience behavioral problems that can include changes in their personality, agitation, anxiety, delusions or hallucinations. Functional difficulties—such as the ability to balance a checkbook, shop for groceries or perform simple domestic tasks—are key features of Alzheimer’s disease and other dementias. The noted improvement may or may not be the result of improved cognitive function, Yaffe said.

According to Yaffe, participants in the studies done to date didn’t necessarily exhibit symptoms in all three categories of problems associated with AD. She said clinical trials that specifically enroll people with behavioral problems are needed to further resolve the issues associated with the use of the drugs.

Long-term research is also needed to determine the effects of these drugs on both patients and their caregivers during the progression of the disease. “We need to know how the small effects of the drugs translate into long-term benefits, such as improvements in quality of life for patients and decreases in burdens to caregivers,” Yaffe said.



Post a Comment

Featured Products From the ProHealth Store
Ultra EPA  - Fish Oil Vitamin D3 Extreme™ Ultra ATP+, Double Strength


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get Energized with Malic Acid & Magnesium
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health

Natural Remedies

Ubiquinol - A More Advanced Form of the Energy Producing Nutrient CoQ-10 Ubiquinol - A More Advanced Form of the Energy Producing Nutrient CoQ-10
The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health
Restore Youthful Cognition and Well-Being Restore Youthful Cognition and Well-Being
Safely Burn Away Body Fat Safely Burn Away Body Fat
Natural Bladder Control, Go Less and Live More Natural Bladder Control, Go Less and Live More

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2018 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map